Phase 1 MS Clinical Trials

43 active trials · 34 recruiting

43 active phase 1 multiple sclerosis trials are listed here, 34 currently recruiting, sourced from ClinicalTrials.gov.

Phase 1 trials test a new treatment in a small group of people for the first time, mainly to check safety, side effects and dosing. They are rarely about whether the treatment works yet.

Active Phase 1 MS trials

RecruitingPhase 1

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Cilostazol · Leucovorin

1 state250 participantsDetails ›

RecruitingPhase 1

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

rapcabtagene autoleucel (YTB323)

28 participantsDetails ›

RecruitingPhase 1

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

Sponsor: Hoffmann-La Roche

RO7121932 IV · RO7121932 SC

5 states129 participantsDetails ›

RecruitingPhase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Sponsor: National Cancer Institute (NCI)

Biospecimen Collection · Nivolumab

19 states300 participantsDetails ›

RecruitingPhase 1

Obe-cel in Refractory Progressive Forms of Multiple Sclerosis

Sponsor: Autolus Limited

Obecabtagene autoleucel (obe-cel)

1 state18 participantsDetails ›

RecruitingPhase 1

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Sponsor: Tr1X, Inc.

TRX319 · Bendamustine

2 states39 participantsDetails ›

RecruitingPhase 1

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Sponsor: University of California, San Francisco

Clemastine Fumarate · Placebo

1 state74 participantsDetails ›

RecruitingPhase 1

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

89 Zr-Df-crefmirlimab

1 state15 participantsDetails ›

RecruitingPhase 1

A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

Sponsor: Stanford University

KYV-101 anti-CD19 CAR-T cell therapy · Standard lymphodepletion regimen

1 state12 participantsDetails ›

RecruitingPhase 1

Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.

Sponsor: University of Alabama at Birmingham

DPA-714 PET/MRI

1 state120 participantsDetails ›

RecruitingPhase 1

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

CC-97540 · Fludarabine

14 states120 participantsDetails ›

RecruitingPhase 1

An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

Sponsor: AstraZeneca

AZD0120 - Regimen 1 · AZD0120 - Regimen 2

8 states24 participantsDetails ›

RecruitingPhase 1

Molecular Imaging of NET Using [C-11]MRB-PET in MS

Sponsor: Brigham and Women's Hospital

[C-11]Methylreboxetine

1 state19 participantsDetails ›

RecruitingPhase 1

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Sponsor: Brigham and Women's Hospital

[F-18]PBR06 · [C-11]PBR28

1 state250 participantsDetails ›

RecruitingPhase 1

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Sponsor: Beijing Boren Hospital

Autologous CD19-BCMA Dual-Target CAR …

12 participantsDetails ›

RecruitingPhase 1

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

Sponsor: Genentech, Inc.

P-CD19CD20-ALLO1 Cells · Cyclophosphamide

1 state60 participantsDetails ›

RecruitingPhase 1

Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis

Sponsor: Rennes University Hospital

Adipose tissue-derived Mesenchymal St…

10 participantsDetails ›

RecruitingPhase 1

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Sponsor: Novartis Pharmaceuticals

rapcabtagene autoleucel (YTB323)

28 participantsDetails ›

RecruitingPhase 1

A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis

Sponsor: The Hospital for Sick Children

Metformin · Placebo

20 participantsDetails ›

RecruitingPhase 1

A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.

Sponsor: Inventage Lab., Inc.

Vivitrol Injectable Product · IVL3004

40 participantsDetails ›

RecruitingPhase 1

Vancomycin Study in Multiple Sclerosis (MS)

Sponsor: Icahn School of Medicine at Mount Sinai

Vancomycin · Placebo

1 state12 participantsDetails ›

RecruitingPhase 1

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Sponsor: Queen Mary University of London

Ixazomib (NINLARO®) capsules / Matchi…

72 participantsDetails ›

RecruitingPhase 1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients

Sponsor: Vidya Therapeutics Inc

VT7208 · Placebo

100 participantsDetails ›

RecruitingPhase 1

Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis

Sponsor: Ever Supreme Bio Technology Co., Ltd.

Allogeneic umbilical cord mesenchymal… · Control group

41 participantsDetails ›

RecruitingPhase 1

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

Sponsor: RenJi Hospital

CD20/BCMA-directed CAR-T cells

30 participantsDetails ›

RecruitingPhase 1

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

LCAR-AIO T cells

37 participantsDetails ›

RecruitingPhase 1

Exploring the Utility of [18F]3F4AP for Demyelination Imaging

Sponsor: Yale University

[ 18F]3F4AP · [18F]MK6240

1 state105 participantsDetails ›

RecruitingPhase 1

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Sponsor: Ashvattha Therapeutics, Inc.

18F-OP-801

2 states65 participantsDetails ›

RecruitingPhase 1

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS

Sponsor: The Foundation for Orthopaedics and Regenerative Medicine

AlloRx

15 participantsDetails ›

RecruitingPhase 1

Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects

Sponsor: Massachusetts General Hospital

F-18 3F4AP

1 state60 participantsDetails ›

RecruitingPhase 1

Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy with Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients with a First Clinical Episode Highly Suggestive of Multiple Sclerosis

Sponsor: Nantes University Hospital

Cellular therapy with EBV specific au…

7 participantsDetails ›

RecruitingPhase 1

Non-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis

Sponsor: University of Washington

Transcutaneous electrical spinal cord… · Occupational Therapy

1 state4 participantsDetails ›

RecruitingPhase 1

AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple Sclerosis

Sponsor: St. Petersburg State Pavlov Medical University

Fludarabine Phosphate for Injection

200 participantsDetails ›

RecruitingPhase 1

A Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of IMS001 in Subjects With Multiple Sclerosis

Sponsor: ImStem Biotechnology

IMS001

3 states30 participantsDetails ›

By invitation onlyPhase 1

Study of Circadian Focused Light Therapy in Progressive Multiple Sclerosis

Sponsor: University of Texas Southwestern Medical Center

Light therapy

1 state20 participantsDetails ›

By invitation onlyPhase 1

Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting

Sponsor: Truway Health, Inc.

Low-Frequency Electromagnetic Resonan… · Sham Resonance Device (Inactive Control)

1 state120 participantsDetails ›

Closed to new patientsPhase 1

MitoQ for Fatigue in Multiple Sclerosis (MS)

Sponsor: VA Office of Research and Development

20 mg MitoQ · Placebo

1 state45 participantsDetails ›

Closed to new patientsPhase 1

Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis

Sponsor: Haukeland University Hospital

MSCs · Saline

18 participantsDetails ›

Closed to new patientsPhase 1

A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis

Sponsor: Bruce Cree

KYV-101 (Biological) - 0.33 ×10^8 cells · KYV-101 (Biological) - 1 ×10^8 cells

1 state10 participantsDetails ›

Closed to new patientsPhase 1

WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis

Sponsor: Kessler Foundation

GEMS Plus · GEMS

1 state31 participantsDetails ›

Closed to new patientsPhase 1

ABA-101 in Participants With Progressive Multiple Sclerosis

Sponsor: Abata Therapeutics

ABA-101

3 states12 participantsDetails ›

Closed to new patientsPhase 1

Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

Sponsor: Cellerys AG

CLS12311 low · CLS12311 medium

11 participantsDetails ›

Closed to new patientsPhase 1

Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis

Sponsor: Abu Dhabi Stem Cells Center

Extracorporeal Photopheresis · MS standard of care

15 participantsDetails ›

MS trials by phase

Phase 2 (60)Phase 3 (49)Phase 4 (19)

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.